Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Transl Res. 2018 Oct;200:18-34. doi: 10.1016/j.trsl.2018.05.001. Epub 2018 May 22.
Vaccination seems to be the best approach to control visceral leishmaniasis (VL). Resistance against infection is based on the development of a Th1 immune response characterized by the production of interferons-γ (IFN-γ), interleukin-12 (IL-12), granulocyte-macrophage-colony-stimulating factor (GM-CSF), and tumor necrosis factor-α (TNF-α), among others. A number of antigens have been tested as potential targets against the disease; few of them are able to stimulate human immune cells. In the present study, 1 prediction of MHC class I and II molecules-specific epitopes in the amino acid sequences of 3 Leishmania proteins: 1 hypothetical, prohibitin, and small glutamine-rich tetratricopeptide repeat-containing proteins, was performed using bioinformatics tools, and a T-cell epitopes-based recombinant chimeric protein was constructed, synthetized and purified to be evaluated in invitro and in vivo experiments. The purified protein was tested regarding its immunogenicity in peripheral blood mononuclear cells (PBMCs) from healthy subjects and VL patients, as well as to its immunogenicity and protective efficacy in a murine model against Leishmania infantum infection. Results showed a Th1 response based on high IFN-γ and low IL-10 levels derived from in chimera-stimulated PBMCs in both healthy subjects and VL patients. In addition, chimera and/or saponin-immunized mice presented significantly lower parasite burden in distinct evaluated organs, when compared to the controls, besides higher levels of IFN-γ, IL-2, IL-12, and GM-CSF, and an IgG2a isotype-based humoral response. In addition, the CD4 and CD8 T-cell subtypes contributed to IFN-γ production in the protected animals. The results showed the immunogenicity in human cells and the protective efficacy against L. infantum in a murine model, and well indicate that this recombinant chimera can be considered as a promising strategy to be used against human disease.
接种疫苗似乎是控制内脏利什曼病(VL)的最佳方法。抗感染的抵抗力基于 Th1 免疫反应的发展,其特征在于产生干扰素-γ(IFN-γ)、白细胞介素-12(IL-12)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和肿瘤坏死因子-α(TNF-α)等。已经测试了许多抗原作为针对该疾病的潜在靶标;其中很少有能够刺激人类免疫细胞。在本研究中,使用生物信息学工具对 3 种利什曼原虫蛋白的氨基酸序列中的 MHC Ⅰ类和Ⅱ类分子特异性表位进行了预测:1 种假设蛋白、 prohibitin 和富含小谷氨酰胺的 tetratricopeptide repeat-containing 蛋白,并构建了基于 T 细胞表位的重组嵌合蛋白,进行合成和纯化,以在体内和体外实验中进行评估。纯化蛋白在健康受试者和 VL 患者的外周血单核细胞(PBMC)中进行了免疫原性测试,以及在针对利什曼原虫感染的小鼠模型中的免疫原性和保护功效测试。结果显示,在健康受试者和 VL 患者的嵌合刺激 PBMC 中,基于高水平 IFN-γ和低水平 IL-10,产生了 Th1 反应。此外,与对照组相比,嵌合体和/或皂苷免疫的小鼠在不同评估的器官中的寄生虫负荷明显降低,并且 IFN-γ、IL-2、IL-12 和 GM-CSF 水平更高,以及 IgG2a 同种型的体液反应。此外,CD4 和 CD8 T 细胞亚型有助于保护动物中 IFN-γ的产生。这些结果显示了该重组嵌合体在人类细胞中的免疫原性和在小鼠模型中的保护功效,并且很好地表明该重组嵌合体可以被认为是一种有前途的策略,可用于治疗人类疾病。